Andrea Sbrozzi-Vanni

Learn More
BACKGROUND Type I gastric carcinoids (TIGCs) are neuroendocrine neoplasms arising from enterochromaffin-like cells in atrophic body gastritis. Data regarding their evolution in prospective series are scarce, thus treatment and follow-up are not codified. Our aim was to evaluate clinical outcome and recurrence in TIGCs managed by endoscopic approach. (More)
BACKGROUND Long-term observational studies assessing the incidence of type I gastric carcinoid (typeIGC) in patients with chronic atrophic gastritis are few. AIM To evaluate the occurrence of typeIGC at diagnosis and during follow-up and to identify patient features associated with the presence of typeIGC in a cohort of chronic atrophic gastritis(More)
BACKGROUND Peptic ulcer disease (PUD) represents a common condition, although its incidence is decreasing. Previous studies reported a high rate of idiopathic PUD prevalence. AIM To investigate prevalence, relative distribution of etiologic factors and prevalence of complication of PUD in an Italian endoscopic series. MATERIALS AND METHODS All(More)
BACKGROUND Atrophic gastritis of the corporal mucosa is a frequent cause of hypergastrinemia. Hypergastrinemia is implicated in colorectal cancer development. AIM To assess whether hypergastrinemic atrophic gastritis is associated with a higher risk of neoplastic colorectal lesions. METHODS Among 441 hypergastrinemic atrophic gastritis patients, 160 who(More)
Helicobacter pylori eradication rate following standard triple therapy is decreasing. Identification of predictive factors of therapy success would be useful for H. pylori management in clinical practice. This study aimed to evaluate the role of different gastritis patterns on the efficacy of the currently suggested 14-day triple therapy regimen.(More)
  • 1